Acadia Pharmaceuticals

Patent cliffs & loss of exclusivity

Acadia Pharmaceuticals develops and markets medicines for central nervous system disorders and rare diseases, including NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome.

Company

AngelList URLhttps://angel.co/acadia-pharmaceuticals
CAGE Code5LB84
Legal NameACADIA Pharmaceuticals Inc.
Company Operating StatusActive
Crunchbase URLhttps://www.crunchbase.com/organization/acadia-pharmaceuticals
Email format{f}{last}
Fax Number+1 (858) 212-0513
Full Address12830 EL CAMINO REAL #400 SAN DIEGO, CA 92130 UNITED STATES

7 upcoming patent cliffs

DrugIngredientTypeCliff
  1. NUPLAZIDPIMAVANSERIN TARTRATESmall mol.Oct 2030
  2. NUPLAZIDPIMAVANSERIN TARTRATESmall mol.Sep 2037
  3. NUPLAZIDPIMAVANSERIN TARTRATESmall mol.Feb 2039
  4. DAYBUE STIXTROFINETIDESmall mol.Jan 2043
  5. DAYBUE STIXTROFINETIDESmall mol.Jan 2043
  6. DAYBUE STIXTROFINETIDESmall mol.Jan 2043
  7. DAYBUETROFINETIDESmall mol.Jan 2043

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.